Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 158

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 2
Chunk 158
---
:5 Reverse Stock Split and all fractional
shares were rounded up to the nearest whole share with respect to outstanding shares of common stock. Unless otherwise noted, all references
to numbers of shares of our common stock and per share information presented in this Quarterly Report on Form 10-Q have been retroactively
adjusted to reflect the effects of the 1:5 Reverse Stock Split.

January 2025 Offering

On January 28, 2025, we entered into a securities
purchase agreement (the “January 2025 Securities Purchase Agreement”) with certain institutional investors (the “January
2025 Purchasers”) pursuant to which we sold an aggregate of 204,312 shares of common stock at a purchase price of $5.105 per share
in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market LLC (“Nasdaq”). In a concurrent
private placement, we also issued to the January 2025 Purchasers unregistered warrants (the “January 2025 Warrants”) to purchase
up to an aggregate of 408,621 shares of common stock at an exercise price of $3.855 per share. The January 2025 Warrants are exercisable
upon issuance and expire twenty-four months from the date of issuance.

The shares were offered pursuant to a “shelf”
registration statement on Form S-3 (Registration No. 333-280796), which was declared effective by the Securities and Exchange Commission
(the “SEC”) on July 18, 2024 as supplemented by a prospectus supplement dated January 28, 2025, filed with the SEC on January
30, 2025, and accompanying base prospectus, pursuant to Rule 424(b)(5) promulgated under the Securities Act of 1933, as amended (the “Securities
Act”).

H.C. Wainwright & Co., LLC (the “Placement
Agent”) acted as our exclusive placement agent in connection with the offering. Pursuant to the terms of the placement agent agreement,
we paid the Placement Agent a cash transaction fee equal to 7.5% of the aggregate gross cash proceeds in the offering and a management
fee equal to 1.0% of the aggregate gross cash proceeds in the offering. In addition, we paid for certain non-accountable expenses in the
amount of $15,000 and a clearing fee in the amount of $10,000. We also issued to the Placement Agent (or its designees) warrants to purchase